Launch of a Checklist for Reporting Longitudinal Observational Drug Studies in Rheumatology: A EULAR Extension of STROBE Guidelines Based on Experience From Biologics Registries

Ann Rheum Dis. 2014 Mar;73(3):628. doi: 10.1136/annrheumdis-2013-204102. Epub 2013 Sep 20.

Abstract

No abstract available

Keywords: DMARDs (biologic); DMARDs (synthetic); Epidemiology.

Publication types

  • Letter
  • Comment

MeSH terms

  • Adverse Drug Reaction Reporting Systems / organization & administration*
  • Antirheumatic Agents / adverse effects*
  • Biological Products / adverse effects*
  • Humans
  • Registries / standards*
  • Rheumatic Diseases / drug therapy*

Substances

  • Antirheumatic Agents
  • Biological Products